silevertinib (BDTX-1535) monotherapy Clinical Trials (2026): 2 Studies for Advanced Lung Carcinoma & Advanced Non-Small Cell Squamous Lung Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
2 silevertinib (BDTX-1535) monotherapy clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 2 indications (including Advanced Lung Carcinoma & Advanced Non-Small Cell Squamous Lung Cancer) and 362 total planned enrollment. 1 silevertinib (BDTX-1535) monotherapy clinical trial is actively recruiting at 21 U.S. sites across 13 states. Most recent activity: NCT07326566 (Mar 2029).
Where to Participate: All silevertinib (BDTX-1535) monotherapy Trial Sites in the U.S. (21 sites across 13 states)
Every actively recruiting silevertinib (BDTX-1535) monotherapytrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AR | Highlands Oncology Group | Springdale72762 | NCT07326566 | Map |
| CA | Cedars-Sinai Medical Center | Los Angeles90048 | NCT07326566 | Map |
| CT | Yale Cancer Center | New Haven06510 | NCT07326566 | Map |
| DC | Johns Hopkins Sibley Memorial Hospital | Washington D.C.20016 | NCT07326566 | Map |
| FL | Miami Cancer Institute | Miami33176 | NCT07326566 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT07326566 | Map |
| MD | Johns Hopkins Sidney Kimmel Cancer Center - Baltimore | Baltimore21287 | NCT07326566 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT07326566 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT07326566 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT07326566 | Map |
| MI | Henry Ford Cancer- Detroit | Detroit48202 | NCT07326566 | Map |
| MO | Washington University School of Medicine Siteman Cancer Center | St Louis63108 | NCT07326566 | Map |
| NJ | John Theurer Cancer Center at Hackensack University Medical Center | Hackensack07601 | NCT07326566 | Map |
| NJ | Rutgers Cancer Institute | New Brunswick08901 | NCT07326566 | Map |
| NJ | Atlantic Health | Summit07901 | NCT07326566 | Map |
| NY | Northwell Health Center for Advanced Medicine - Brain Tumor Center | Lake Success11042 | NCT07326566 | Map |
| NY | Columbia University Irving Medical Center | New York10032 | NCT07326566 | Map |
| NY | Montefiore Medical Center | The Bronx10461 | NCT07326566 | Map |
| PA | Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center | Philadelphia19107 | NCT07326566 | Map |
| PA | UPMC Hillman Cancer Center | Pittsburgh15232 | NCT07326566 | Map |
| SC | Prisma Health | Greenville29605 | NCT07326566 | Map |
silevertinib (BDTX-1535) monotherapy clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | Total |
|---|---|---|---|
| P1/P2 | 1 | 1 | |
| P2 | 1 | 1 |
Recruiting silevertinib (BDTX-1535) monotherapy clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07326566 | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII | P2 | Glioblastoma (GBM) | 162 | May 2026 |
silevertinib (BDTX-1535) monotherapy clinical trials by indication
Glioblastoma (GBM) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07326566 | — | P2 | recruiting | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII |
Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05256290 | BDTX-1535 | P1/P2 | active not recruiting | Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations |
All silevertinib (BDTX-1535) monotherapy trials (2)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07326566 | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII | P2 | recruiting | 162 | Black Diamond Therapeutics, Inc. | May 2026 | |
| NCT05256290 | BDTX-1535 | Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations | P1/P2 | active not recruiting | 200 | Black Diamond Therapeutics, Inc. | Mar 2022 |
silevertinib (BDTX-1535) monotherapy clinical trials: frequently asked questions
- How many silevertinib (BDTX-1535) monotherapy clinical trials are there?
- 2 silevertinib (BDTX-1535) monotherapy clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are silevertinib (BDTX-1535) monotherapy clinical trials recruiting in 2026?
- Yes — 1 silevertinib (BDTX-1535) monotherapy trial is actively recruiting in 2026, with 21 U.S. sites across 13 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is silevertinib (BDTX-1535) monotherapy being studied for?
- silevertinib (BDTX-1535) monotherapy is being studied for Advanced Lung Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer, Brain Cancer, Central Nervous System Diseases, EGF-R Positive Non-Small Cell Lung Cancer and 12 more. The trials are grouped by indication on this page.
- What phase is silevertinib (BDTX-1535) monotherapy in?
- silevertinib (BDTX-1535) monotherapy clinical trials span 1 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors silevertinib (BDTX-1535) monotherapy clinical trials?
- The lead sponsor across the most silevertinib (BDTX-1535) monotherapy trials is Black Diamond Therapeutics, Inc.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming silevertinib (BDTX-1535) monotherapyas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: